Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer-Impact for Diagnosis and Treatment Monitoring.
debulking surgery
disease monitoring
epithelial ovarian cancer
high-grade
liquid biopsy
tumor burden
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Dec 2021
30 Dec 2021
Historique:
received:
12
11
2021
revised:
16
12
2021
accepted:
20
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
Chromosomal instability, a hallmark of cancer, results in changes in the copy number state. These deviant copy number states can be detected in the cell-free DNA (cfDNA) and provide a quantitative measure of the ctDNA levels by converting cfDNA next-generation sequencing results into a genome-wide copy number instability score (CNI-Score). Our aim was to determine the role of the CNI-Score in detecting epithelial ovarian cancer (EOC) and its role as a marker to monitor the response to treatment. Blood samples were prospectively collected from 109 patients with high-grade EOC. cfDNA was extracted and analyzed using a clinical-grade assay designed to calculate a genome-wide CNI-Score from low-coverage sequencing data. Stored data from 241 apparently healthy controls were used as a reference set. Comparison of the CNI-Scores of primary EOC patients versus controls yielded sensitivities of 91% at a specificity of 95% to detect OC, respectively. Significantly elevated CNI-Scores were detected in primary (median: 87, IQR: 351) and recurrent (median: 346, IQR: 1891) blood samples. Substantially reduced CNI-Scores were detected after primary debulking surgery. Using a cut-off of 24, a diagnostic sensitivity of 87% for primary and recurrent EOC was determined at a specificity of 95%. CNI-Scores above this threshold were detected in 21/23 primary tumor (91%), 36/42 of platinum-eligible recurrent (85.7%), and 19/22 of non-platinum-eligible recurrent (86.3%) samples, respectively. ctDNA-quantification based on genomic instability determined by the CNI-Score was a biomarker with high diagnostic accuracy in high-grade EOC. The applied assay might be a promising tool for diagnostics and therapy monitoring, as it requires no a priori information about the tumor.
Sections du résumé
BACKGROUND
BACKGROUND
Chromosomal instability, a hallmark of cancer, results in changes in the copy number state. These deviant copy number states can be detected in the cell-free DNA (cfDNA) and provide a quantitative measure of the ctDNA levels by converting cfDNA next-generation sequencing results into a genome-wide copy number instability score (CNI-Score). Our aim was to determine the role of the CNI-Score in detecting epithelial ovarian cancer (EOC) and its role as a marker to monitor the response to treatment.
METHODS
METHODS
Blood samples were prospectively collected from 109 patients with high-grade EOC. cfDNA was extracted and analyzed using a clinical-grade assay designed to calculate a genome-wide CNI-Score from low-coverage sequencing data. Stored data from 241 apparently healthy controls were used as a reference set.
RESULTS
RESULTS
Comparison of the CNI-Scores of primary EOC patients versus controls yielded sensitivities of 91% at a specificity of 95% to detect OC, respectively. Significantly elevated CNI-Scores were detected in primary (median: 87, IQR: 351) and recurrent (median: 346, IQR: 1891) blood samples. Substantially reduced CNI-Scores were detected after primary debulking surgery. Using a cut-off of 24, a diagnostic sensitivity of 87% for primary and recurrent EOC was determined at a specificity of 95%. CNI-Scores above this threshold were detected in 21/23 primary tumor (91%), 36/42 of platinum-eligible recurrent (85.7%), and 19/22 of non-platinum-eligible recurrent (86.3%) samples, respectively.
CONCLUSION
CONCLUSIONS
ctDNA-quantification based on genomic instability determined by the CNI-Score was a biomarker with high diagnostic accuracy in high-grade EOC. The applied assay might be a promising tool for diagnostics and therapy monitoring, as it requires no a priori information about the tumor.
Identifiants
pubmed: 35008332
pii: cancers14010168
doi: 10.3390/cancers14010168
pmc: PMC8750971
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Oncol. 2019 May 1;30(5):672-705
pubmed: 31046081
Clin Cancer Res. 2017 May 1;23(9):2223-2231
pubmed: 27852697
Ann Oncol. 2021 Sep;32(9):1167-1177
pubmed: 34176681
J Natl Cancer Inst. 2003 Sep 3;95(17):1320-9
pubmed: 12953086
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
N Engl J Med. 2021 Dec 2;385(23):2123-2131
pubmed: 34874631
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cold Spring Harb Perspect Med. 2017 Jan 3;7(1):
pubmed: 28049655
Sci Adv. 2020 Dec 11;6(50):
pubmed: 33310847
Lancet. 2010 Oct 2;376(9747):1155-63
pubmed: 20888993
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
BMC Med. 2016 Aug 24;14(1):126
pubmed: 27558279
Clin Chem. 2018 Jun;64(6):959-970
pubmed: 29661793
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
PLoS Med. 2016 Dec 20;13(12):e1002198
pubmed: 27997533
PLoS Genet. 2016 Jul 18;12(7):e1006162
pubmed: 27428049
J Clin Oncol. 2018 Jun 1;36(16):1631-1641
pubmed: 29504847
Genome Res. 2014 Dec;24(12):2022-32
pubmed: 25236618
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Am J Transplant. 2019 Nov;19(11):3087-3099
pubmed: 31062511
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Sci Rep. 2019 Oct 22;9(1):15017
pubmed: 31641155
Sci Transl Med. 2017 Aug 16;9(403):
pubmed: 28814544
Clin Cancer Res. 2017 Sep 1;23(17):5074-5081
pubmed: 28320758
NAR Genom Bioinform. 2020 Jun;2(2):lqaa021
pubmed: 32363341
Nature. 2020 Apr;580(7802):245-251
pubmed: 32269342